Biodesix, Inc. (BDSX)

NASDAQ: BDSX · IEX Real-Time Price · USD
3.81
-0.43 (-10.14%)
At close: Jan 21, 2022 4:00 PM
3.83
0.02 (0.52%)
After-hours:Jan 21, 2022 5:56 PM EST

Company Description

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States.

The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions.

It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection.

In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics.

The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Biodesix, Inc.
Biodesix Logo
CountryUnited States
IPO DateOct 28, 2020
IndustryDiagnostics & Research
SectorHealth Care
Employees200

Contact Details

Address:
2970 Wilderness Place
Boulder, CO 80301
United States
Phone303 417 0500
Websitebiodesix.com

Stock Details

Ticker SymbolBDSX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$18.00
CIK Code0001439725

Key Executives

NamePosition
Scott HuttonPresident, Chief Executive Officer and Director
Robin Harper CowieChief Financial Officer, Secretary and Treasurer
Kieran O'KaneChief Commercial Officer
Dr. Heinrich RöderFounder and Chief Technology Officer
Robert E. CawthornFounder and Director Emeritus
Ryan H. SiurekChief Accounting Officer
Jeffrey A. BojarVice President of Legal and Regulatory Affairs
Matt StaufferVice President of Sales
Dr. Paul J. BeresfordChief Business Officer
Dr. Gary Anthony Pestano Ph.D.Chief Development Officer

Latest SEC Filings

DateTypeTitle
Jan 10, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 10, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Jan 7, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 4, 20224Statement of changes in beneficial ownership of securities
Jan 4, 20224Statement of changes in beneficial ownership of securities
Jan 4, 20224Statement of changes in beneficial ownership of securities
Jan 4, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Jan 4, 20228-KCurrent report
Dec 22, 20214Statement of changes in beneficial ownership of securities
Dec 22, 2021424B5Prospectus [Rule 424(b)(5)]
View All SEC Filings